Blackpool CCG Medicines Optimisation

Blackpool CCG Medicines Optimisation

Medicines play an important part in promoting well-being, preventing ill-health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines Management can be defined in several ways:

The clinical, cost-effective, safe and secure handling of medicines
A system of processes and behaviours that determines how medicines are used by the NHS and patients
Enabling people to make the best possible use of medicines
Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s Medicines Management team on 01253 951306 or email


Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

Prescribing guidance

Axial-Spondyloarthritis-pathway-Version 37 KB43
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB51
Chronic-Non-cancer-Pain-Guidelines-Version 1.2 MB48
Colomycin prescribing information sheet Non CF indications. 0.2 MB26
Constipation-Pathway-Version 0.7 MB49
COPD guideline 0.6 MB7
Diabetes - Algorithm for antihyperglycaemic therapy in adults with type II Diabetes 0.6 MB44
Diabetes - BG meters and test strips Type-2-Diabetes 0.5 MB114
Diabetes - Glucagon Like Peptide Contract 0.2 MB59
Diabetes - Home Monitoring of Blood Glucose Levels Guidelines 0.3 MB45
Diabetes-self-management-contract 0.5 MB72
Edoxaban Prescribing Tip 68 KB79
Erectile-Dysfunction-Guideline-Version 1.0 MB60
Flash Glucose Monitoring policy - L&SC 0.2 MB7
Gastroenterology-Biologics-Pathway-Version 0.4 MB62
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB47
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB75
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB19
Headache Management Guideline for Adults 0.7 MB25
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB48
Interim Gender Dysphoria protocol 0.6 MB33
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB48
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB40
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB82
Neuropathic Pain Guidance (Version 1.2) 0.9 MB39
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB55
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB42
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB57
Primary Care Good Prescribing Guide 0.6 MB67
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB54
Psoriasis-LMMG-Biologic-and-High-Cost-Drug-Commissioning-Pathway-Version 0.8 MB53
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB63
RA-High-Cost-Drugs-Pathway-v 0.2 MB54
Restless Legs Syndrome guidelines 0.3 MB23
SIP Feeds 0.1 MB53
Wound care formulary 8.2 MB71

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document:

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place (October 2018):

  • Fencino (Fentanyl) – Started 1 October 2018
  • Firmagon (Degarelix) – Started 1 September 2016
  • Januvia (Sitagliptin)  – Started 1 September 2018
  • Lixiana (Edoxaban) – Started 1 October 2018
  • Seretide (Fluticasone / Salmeterol) – Started 1 January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started 1 October 2018

Last updated on 22 May 2019 at 13:26 by communications and engagement manager